Skip to main content
      RT @swethaann23: Minimal disease activity achievement in PsA achieved by 22.8% in 6 mo of b/ts DMARD

      MDA achievers were

      swethaann23 swethaann23

      4 years ago
      Minimal disease activity achievement in PsA achieved by 22.8% in 6 mo of b/ts DMARD MDA achievers were: ➡️Younger ➡️🔽 Disease duration; ➡️ Male ➡️Non-obese ➡️bDMARD-naïve at baseline ➡️🔼 probability achieving MDA components➕MCID PROMs at 6 mo Abst# 1344 #ACR21 @Rheumnow
      RT @RichardPAConway: Effect of BMI on PRO treatment response in PsA. Increasing BMI associated with lower response. More

      Richard Conway RichardPAConway

      4 years ago
      Effect of BMI on PRO treatment response in PsA. Increasing BMI associated with lower response. More pronounced in TNFi than IL-17 or JAKi. Abstr#1327 #ACR21 @RheumNow https://t.co/qhgVlW72uM
      RT @RHEUMarampa: In this study,
      ⭕AS pts w/>=2 #comorbidities were associated w/ poorer outcome measures after 2 yr

      sheila RHEUMarampa

      4 years ago
      In this study, ⭕AS pts w/>=2 #comorbidities were associated w/ poorer outcome measures after 2 yrs of ffup vs. pts w/ no comorbids ⭕Pts w/ >=2 comorbids were likely to dc 1st anti-TNF Address comorbidities, ⬆ chances of better outcomes & QoL @RheumNow #ACR21 abs1309 https://t.co/sTnjaC1a1l
      RT @ericdeinmd: #ACR21 Abs#1225: B/L Extracell Matrix Biomarkers predict ABA response in MTX-naive, +ACPA early RA
      ⭐ï¸

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abs#1225: B/L Extracell Matrix Biomarkers predict ABA response in MTX-naive, +ACPA early RA ⭐️ECM biomarkers predict SDAI remission or DAS28 w ABA+MTX vs PBO+MTX. ⭐️⬆️CTX1 biomarker predicts efficacy endpts for ABA+MTX https://t.co/7wHQefb5D4 @Rheumnow
      RT @DrMiniDey: Wk 12 disease activity predicts wk 24/26 remission/low disease activity with #upadacitinib 15mg in MTX-na

      Mrinalini Dey DrMiniDey

      4 years ago
      Wk 12 disease activity predicts wk 24/26 remission/low disease activity with #upadacitinib 15mg in MTX-naïve or inadequate responders to MTX and/or TNFi pts. ≥50% improvement in SJC/TJC at Wk 12 was assoc with wk 24/26 remission/low disease activity. Abs#1237 #ACR21 @RheumNow https://t.co/PAaCe5MAcu
      RT @ericdeinmd: #ACR21 - Starting soon - The Gift of Gab! with @BayviewMedicine @jhrheumatology Jason Liebowitz moderati

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 - Starting soon - The Gift of Gab! with @BayviewMedicine @jhrheumatology Jason Liebowitz moderating Communication for the Physician with @Wharton Janet Zeide. Learn about the RHEUM acronym for speaking! @Rheumnow https://t.co/wcgFUBcZeX
      RT @synovialjoints: EULAR update on vaccines. HZ vaccine safe with csDMARDs and TNFα blockers. Reduced cell immune resp

      Dr. Antoni Chan synovialjoints

      4 years ago
      EULAR update on vaccines. HZ vaccine safe with csDMARDs and TNFα blockers. Reduced cell immune response after 1 year. Assess Varicella Abs if exposure unknown. Non-live recombinant subunit adjuvant zoster vaccine may be a game changer @RheumNow #ACR21 8M101 https://t.co/PTLqYGRIGf
      RheumNow’s expanded coverage of #ACR21 is sponsored in part by @Novartis. All content chosen by RheumNow & its Fac

      Dr. John Cush RheumNow

      4 years ago
      RheumNow’s expanded coverage of #ACR21 is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
      RT @DrMiniDey: Abs#1036: illness-related uncertainty significantly correlates with #depression, #anxiety, and sickness i

      Mrinalini Dey DrMiniDey

      4 years ago
      Abs#1036: illness-related uncertainty significantly correlates with #depression, #anxiety, and sickness impact in patients with autoimmune #rheumaticdiseases. Particularly strong associations with #AAV and #SSc. #MentalHealth #ACR21 @RheumNow https://t.co/SiV9fst3Bh https://t.co/w8VRQHdAJC
      RT @AurelieRheumo: ⚡️A new biomarker of structural progression in RA? Plasma levels of CXCL13 ⬆️ @ baseline vs.

      Aurelie Najm AurelieRheumo

      4 years ago
      ⚡️A new biomarker of structural progression in RA? Plasma levels of CXCL13 ⬆️ @ baseline vs. ctrl and ⬇️ (p< 0.0001) after 1 yr treatment in a eRA cohort. Levels above 85pg/ml ⬆️ x5 risk of > severe radiographic status at 11yrs. @RheumNow #ACR21 #Abst1204 https://t.co/LnkayR1YrY https://t.co/W0xsgGuUDW
      RT @ericdeinmd: #ACR21 Abst#1204. CXCL13 predicts long-term radiographic status in early RA
      ▶️ early RA has ⬆️ C

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abst#1204. CXCL13 predicts long-term radiographic status in early RA ▶️ early RA has ⬆️ CXCL13, and ⬇️ w treatment ⭐️CXCL13 was best predictor of long-term radiographic destruction - better than DAS28CRP and CRP @Rheumnow https://t.co/ydYRbKMBZ2 https://t.co/qinEFb86Az
      RT @ericdeinmd: #ACR21 Abst#1229: Does BMI influence efficacy of SC (fixed dose) vs IV (body-wt adjusted) ABA in RA?
      ⭐

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abst#1229: Does BMI influence efficacy of SC (fixed dose) vs IV (body-wt adjusted) ABA in RA? ⭐️No difference between SC and IV ABA by BMI ⭐️BMI impacts response to ABA as >2nd line therapy and retention, but no difference bw dosing https://t.co/LqfZvLhBzU @Rheumnow
      ×